Glenmark launches generic ophthalmic solution in US market

Glenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in the US market. The product matches Upjohn US LLC's Xalatan Ophthalmic Solution, which had annual sales of USD 113.5 million. This launch reflects Glenmark's growing ophthalmic portfolio and commitment to quality solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/g7fTitp
via IFTTT